Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 500

1.

Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.

Reifenberger J, Knobbe CB, Sterzinger AA, Blaschke B, Schulte KW, Ruzicka T, Reifenberger G.

Int J Cancer. 2004 Apr 10;109(3):377-84.

2.

Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.

Akslen LA, Puntervoll H, Bachmann IM, Straume O, Vuhahula E, Kumar R, Molven A.

Melanoma Res. 2008 Feb;18(1):29-35. doi: 10.1097/CMR.0b013e3282f32517.

PMID:
18227705
3.

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.

Tsao H, Goel V, Wu H, Yang G, Haluska FG.

J Invest Dermatol. 2004 Feb;122(2):337-41.

4.

Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.

Lázár V, Ecsedi S, Vízkeleti L, Rákosy Z, Boross G, Szappanos B, Bégány A, Emri G, Adány R, Balázs M.

Melanoma Res. 2012 Jun;22(3):202-14. doi: 10.1097/CMR.0b013e328352dbc8.

PMID:
22456166
5.

NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.

Omholt K, Platz A, Kanter L, Ringborg U, Hansson J.

Clin Cancer Res. 2003 Dec 15;9(17):6483-8.

6.

RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma.

Kang S, Lee JM, Jeon ES, Lee S, Kim H, Kim HS, Seo SS, Park SY, Sidransky D, Dong SM.

Int J Cancer. 2006 Sep 15;119(6):1316-21.

7.

Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.

Knobbe CB, Reifenberger J, Reifenberger G.

Acta Neuropathol. 2004 Dec;108(6):467-70.

PMID:
15517309
8.

Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.

Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DS.

Cancer Res. 2003 Apr 1;63(7):1639-43.

9.
10.

BRAF alterations are associated with complex mutational profiles in malignant melanoma.

Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, Torre GD, Perrone F, Luoni C, Suardi S, Frattini M, Pilotti S, Anichini A, Tragni G, Parmiani G, Pierotti MA, Rodolfo M.

Oncogene. 2004 Aug 5;23(35):5968-77.

PMID:
15195137
11.

BRAF and NRAS mutations in melanoma and melanocytic nevi.

Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, Redman B, Thomas NE, Gruber SB.

Melanoma Res. 2006 Aug;16(4):267-73.

PMID:
16845322
12.

Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC.

Reifenberger J, Knobbe CB, Wolter M, Blaschke B, Schulte KW, Pietsch T, Ruzicka T, Reifenberger G.

Int J Cancer. 2002 Aug 10;100(5):549-56.

13.

[Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].

Lázár V.

Magy Onkol. 2013 Jun;57(2):96-9. doi: MagyOnkol.2013.57.2.96. Hungarian.

14.

BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.

Wong CW, Fan YS, Chan TL, Chan AS, Ho LC, Ma TK, Yuen ST, Leung SY; Cancer Genome Project..

J Clin Pathol. 2005 Jun;58(6):640-4. Review.

15.

Frequent involvement of ras-signalling pathways in both polypoid-type and flat-type early-stage colorectal cancers.

Noda H, Kato Y, Yoshikawa H, Arai M, Togashi K, Nagai H, Konishi F, Miki Y.

J Exp Clin Cancer Res. 2006 Jun;25(2):235-42.

PMID:
16918136
16.

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG.

J Invest Dermatol. 2006 Jan;126(1):154-60.

17.

Inactivation of the RASSF1A in osteosarcoma.

Lim S, Yang MH, Park JH, Nojima T, Hashimoto H, Unni KK, Park YK.

Oncol Rep. 2003 Jul-Aug;10(4):897-901.

PMID:
12792742
18.

Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.

Yaman B, Akalin T, Kandiloğlu G.

Am J Dermatopathol. 2015 May;37(5):389-97. doi: 10.1097/DAD.0000000000000241.

PMID:
25357015
19.

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, Pagani E, Casula M, Manca A, Sini M, Franco R, Botti G, Caracò C, Mozzillo N, Ascierto PA, Palmieri G.

J Clin Oncol. 2012 Jul 10;30(20):2522-9. doi: 10.1200/JCO.2011.41.2452.

PMID:
22614978
20.

Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.

Eskandarpour M, Hashemi J, Kanter L, Ringborg U, Platz A, Hansson J.

J Natl Cancer Inst. 2003 Jun 4;95(11):790-8.

Items per page

Supplemental Content

Support Center